Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD



Status:Recruiting
Conditions:Depression, Depression, Major Depression Disorder (MDD)
Therapuetic Areas:Psychiatry / Psychology, Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - 80
Updated:3/27/2019
Start Date:May 1, 2017
End Date:January 2022
Contact:Max Martinson
Email:mmartinson@partners.org
Phone:6177242784

Use our guide to learn which trials are right for you!

Augmentation Versus Switch: Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With Treatment Resistant Depression (ASCERTAIN-TRD)

This is a multi-site, randomized, open-label, effectiveness trial comparing three treatment
arms for Major Depressive Disorder (MDD) patients with TRD who are currently on ongoing,
stable and adequate antidepressant therapy (ADT). Adequate ADT is defined as a
therapeutically sufficient dose for a sufficient treatment period, which would be expected to
be effective as listed in the MGH Antidepressant Treatment Response Questionnaire (ATRQ).
Patients will be randomized in a 1:1:1 fashion to one of three open-label treatment arms: a)
aripiprazole augmentation, b) rTMS augmentation, and c) switching to venlafaxine XR or
Duloxetine.


Inclusion Criteria:

1. women and men ages 18-80,

2. with MDD, of at least 12 weeks duration, according to Diagnostic and Statistical
Manual of Mental Disorders, Fifth Edition (DSM-5) criteria confirmed by the Mini
International Neuropsychiatric Interview (MINI; Sheehan et al, 1998),

3. have a Montgomery-Asberg Depression Rating Scale (MADRS - Montgomery and Asberg, 1979)
score of at least 20 at screen and baseline as assessed by site clinicians,

4. meet criteria for TRD during the current major depressive episode documented in the
MGH Antidepressant Treatment History Questionnaire (ATRQ) (Chandler et al., 2010),
which will be defined as being non-responders (less than 50% of symptom improvement)
to two or more depression treatment trials of adequate dose and duration as defined by
the MGH ATRQ,

5. are currently on an antidepressant of adequate dose (as defined by the MGH ATRQ) and
duration (at least 8 weeks), with the antidepressant dose being stable over the past
four weeks, and with documented (in the MGH ATRQ) non-response (less than 50%
improvement) to the current antidepressant.

6. Patients who have passed the MGH CTNI remote assessment, with documentation provided
to sites by MGH CTNI.

Exclusion Criteria:

1. pregnant or breastfeeding women, women of childbearing potential who are not using an
accepted means of birth control, or women with a positive urine pregnancy test,

2. patients who have received treatment with rTMS, aripiprazole, electroconvulsive
therapy (ECT), or venlafaxine during the current episode,

3. patients who express an objection to receiving treatment with at least one of the
three treatment arms of our study,

4. patients with any history of bipolar disorder or psychosis (diagnosed by MINI),

5. patients with active alcohol or substance abuse disorders within the past 6 months
(diagnosed by MINI),

6. patients with suicidal ideation of the degree that, in the opinion of the evaluating
clinician, participation in the study would place them at significantly increased risk
of suicide,

7. patients with unstable medical issues of such degree that, in the opinion of the
evaluating clinician, participation in the study would place them at significant risk
of a serious adverse event, or patients with a screening hemoglobin A1c level greater
than 7.5%, or patients with epilepsy, dementia, Parkinson's disease, or Huntington's
Disease,

8. patients who have received treatment with vagus nerve stimulation (VNS),

9. patients who have not responded to more than five FDA-approved antidepressant
treatment trials of adequate dose and duration during the current episode, or who did
not respond to ECT in previous episodes

10. patients on excluded medications,

11. patients with a positive urine screen drug test for a substance for which they do not
have a valid prescription for a valid medical reason,

12. patients with currently abnormal thyroid function tests,

13. patients who have received at least one dose of a monoamine oxidase inhibitor (MAOI)
four weeks or less prior, and

14. for patients on concomitant psychotropic agents (anticonvulsants, benzodiazepines,
hypnotics, opiates, triiodothyronine (T3), modafinil, psychostimulants, buspirone,
melatonin, omega-3 fatty acids, folate, l-methylfolate, s-adenosyl methionine,
lithium) not on the same dose for at least four weeks prior to study entry or who do
not agree to continue at the same dose during the acute phase of the study.

15. Patients who do not meet safety criteria for TMS: history of seizures, cardiac
pacemaker, DBS or VNS, brain aneurism clips or other metallic implants in the
intracranial space.

16. Also excluded is an individual who has received any administration of ketamine in the
current episode for the treatment of depression.
We found this trial at
17
sites
1801 Inwood Rd
Dallas, Texas 75390
(214) 645-3300
University of Texas Southwestern Medical Center UT Southwestern is an academic medical center, world-renowned for...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
1200 Moursund Street
Houston, Texas 77030
(713) 798-4951
Baylor College of Medicine Baylor College of Medicine in Houston, the only private medical school...
?
mi
from
Houston, TX
Click here to add this to my saved trials
4202 E Fowler Ave
Tampa, Florida 33620
(813) 974-2011
University of South Florida The University of South Florida is a high-impact, global research university...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
701 West Pratt Street
Baltimore, Maryland 21204
Phone: 410-938-3000
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Birmingham, Alabama 35294
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Boston, Massachusetts 02114
Phone: 617-724-5198
?
mi
from
Boston, MA
Click here to add this to my saved trials
Charleston, South Carolina 29401
Phone: 843-792-1414
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Charlottesville, Virginia 22908
Phone: 847-869-1500
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
2600 Clifton Ave
Cincinnati, Ohio 45267
(513) 556-6000
Phone: 513-558-7700
University of Cincinnati The University of Cincinnati offers students a balance of educational excellence and...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Los Angeles, California 90095
Phone: 310-825-9989
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
70 Washington Square S
New York, New York 10012
(212) 998-1212
New York University More than 175 years ago, Albert Gallatin, the distinguished statesman who served...
?
mi
from
New York, NY
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
450 Serra Mall
Stanford, California 94305
(650) 723-2300
Stanford University Stanford University, located between San Francisco and San Jose in the heart of...
?
mi
from
Stanford, CA
Click here to add this to my saved trials
Vancouver, British Columbia V6T 1W5
Phone: 604-822-7512
?
mi
from
Vancouver,
Click here to add this to my saved trials
Wichita, Kansas 67214
?
mi
from
Wichita, KS
Click here to add this to my saved trials